Daclizumab

Zenapax

BrazilCancelledAuthorised 16 Mar 1999

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Daclizumab

Zenapax

BrazilCancelledAuthorised 16 Mar 1999

Ask Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Zinbryta

United States · 150MG/ML · injectable · Biogen

ZinbrytaUnited States · 150MG/ML · Injection · Biogen Inc.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Anvisa, Brazil

Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.

Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Daclizumab
Register: Brazil (Anvisa)
Status: Cancelled
Status in the register: Inativo
Authorised: 16 Mar 1999
Registration: 101000550
Marketing authorisation holder: Produtos Roche Químicos e Farmacêuticos S.A.
Procedure: Registered